Progression of Serosal Vascular Proliferative Lesions to Hemangiosarcomas in the Uterus of the 26-Week Tg.rasH2 Mice Carcinogenicity Studies
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Toxicology"
DOI: 10.1177/1091581816659068
Abstract: Tg.rasH2 mice are predisposed to hemangiosarcomas. Following the spleen, the uterus is the second most commonly affected organ in the female mice. Female mice are also predisposed to spontaneous vascular proliferative lesions on the serosal… read more here.
Keywords: rash2 mice; vascular proliferative; proliferative lesions; progression serosal ... See more keywords
Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Toxicology"
DOI: 10.1177/1091581817707458
Abstract: Our recent retrospective analysis of data, collected from 29 Tg.rasH2 mouse carcinogenicity studies, determined how successful the strategy of choosing the high dose for the 26-week studies was based on the estimated maximum tolerated dose… read more here.
Keywords: rash2 mice; cbyb6f1 mice; week; carcinogenicity studies ... See more keywords
Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Toxicology"
DOI: 10.1177/10915818221113295
Abstract: Pretomanid is a nitroimidazooxazine antimycobacterial drug that was approved as part of a three-drug oral regimen, consisting of bedaquiline, pretomanid, and linezolid, for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis or with complicated… read more here.
Keywords: rash2 mice; pretomanid; potential pretomanid; carcinogenic potential ... See more keywords
Survey of tumorigenic sensitivity in 6-month rasH2-Tg mice studies compared with 2-year rodent assays
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Toxicologic Pathology"
DOI: 10.1293/tox.2021-0031
Abstract: The pharmacokinetic endpoint of a 25-fold increase in human exposure is one of the specified criteria for high-dose selection for 2-year carcinogenicity studies in rodents according to ICH S1C(R2). However, this criterion is not universally… read more here.
Keywords: rash2 mice; year; rodent; rash2 mouse ... See more keywords
Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Toxicologic Pathology"
DOI: 10.1293/tox.2022-0040
Abstract: In subcutaneous tumor models, changes in the tumor microenvironment can lead to differences in therapeutic treatment responses between the subcutaneous and parent tumors. Accordingly, we generated a lung carcinogenesis model that combines genetically modified mice… read more here.
Keywords: tumor model; rash2 mice; lung tumor; model ... See more keywords